Use of transcranial direct current stimulation on fatigue in patients with stroke

Effect of transcranial direct current stimulation on fatigue in stroke survivors

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040657

Enrollment

Registered

2022-02-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I639- Cerebral infarction, unspecified

Interventions

Intervention1: Transcranial direct current stimulation (tDCS): Participants will recieve 2mA of tDCS for 20min/day for either 5/4/3/2/1 sessions for 4 weeks Intervention2: Phase 2: Transcranial direct

Eligibility

Inclusion criteria

Inclusion criteria: Phase 1: 1) Age: 18 to 65 years 2) Either gender 3) Late Sub-acute and Chronic stroke survivors 4) Participants who report fatigue as one of their symptoms (VAFS >4) 5) Brunnstorm VC grading of affected UL and LL >=3 Phase 2: 1) Age: 18 to 65 years 2) Either gender 3) Chronic stroke survivors ( 4) Participants who report fatigue (FSS >= 3) 5) Brunnstrom VC grading of UL and LL >= 3

Exclusion criteria

Exclusion criteria: Phase 1: 1) Participants with co-existing disorders of other systems influencing fatigue like chronic fatigue syndrome, cancer, asthma 2) Undergoing treatment with centrally acting medications or immune modulatory drugs affecting the level of fatigue 3) Infratentorial strokes 4) Any cognitive disorders (MoCA 5) Participants with Aphasia 6) Recurrent/ Bilateral/ operated stroke survivors 7) Patients with depression (PHQ-9 >=10) and sleep disorders (ESS >=10) 8) History of epilepsy/ seizure 9) Metal implants/ cardiac pacemaker/ implanted neuro-stimulator Phase 2: 1) Patients with co-existing disorders of other systems influencing fatigue like chronic fatigue syndrome, cancer, asthma 2) Undergoing treatment with centrally acting medications or immune modulatory drugs affecting the level of fatigue 3) Infratentorial strokes 4) Patients with depression (PHQ-9 >=10) and sleep disorders (ESS >=10) 5) Any cognitive disorders (MoCA 6) Recurrent/ Bilateral/ Operated Stroke 7) Participants with Aphasia 8) Participants undergoing a regular structured physiotherapy intervention 9) History of epilepsy/ seizure 10) Metal implants/ cardiac pacemaker/ implanted neuro-stimulator

Design outcomes

Primary

Measure	Time frame
Phase 1: 1) Average scores of Fatigue severity scale 2) % MVC and duration of MVC of affected elbow flexors and knee extensors using EMG 3) Scores of neuropsychological tests Phase 2: 1) Average scores of Fatigue severity scale 2) % MVC and duration of MVC of affected elbow flexors and knee extensors using EMG 3) Individualized physical activity behavior chart with scores of VAFS in cms for each behaviorTimepoint: Phase 1: Baseline, after 2 weeks Phase 2: Baseline, end of each week for 4 weeks, 1 month, 3 months and 6 months	—

Measure

Time frame

Phase 1: 1) Average scores of Fatigue severity scale 2) % MVC and duration of MVC of affected elbow flexors and knee extensors using EMG 3) Scores of neuropsychological tests Phase 2: 1) Average scores of Fatigue severity scale 2) % MVC and duration of MVC of affected elbow flexors and knee extensors using EMG 3) Individualized physical activity behavior chart with scores of VAFS in cms for each behaviorTimepoint: Phase 1: Baseline, after 2 weeks Phase 2: Baseline, end of each week for 4 weeks, 1 month, 3 months and 6 months

—

Secondary

Measure	Time frame
Phase 2: 1) Scores of Mobility Disability Scale 2) Scores of Stroke-specific QOL scaleTimepoint: Phase 2: Baseline, end of each week for 4 weeks, 1 month, 3 months and 6 months	—

Countries

India

Contacts

Public ContactDr John Solomon M

Manipal Academy of Higher Education

john.solomon@manipal.edu9945670671

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 9, 2026